FridayAug 25, 2017 1:47 pm

Does Marijuana’s Move to Mainstream Status Mean Shedding its Counterculture Reputation?

Not that many years ago, if marijuana was discussed in mixed company, it was only talked about in hushed tones, coupled with furtive glances. The “devil’s lettuce” had its fans, of course, but for most folks the topic conjured up images of Hollywood movies characterizing users as stoners who did nothing but smoke weed 24/7 and get in lots of trouble. Fast forward to 2017. Not only is marijuana, or cannabis, discussed around the dinner table in many homes, it’s a topic for investors and in boardrooms as it gains traction as a viable business venture. No fewer than 29…

Continue Reading

FridayAug 25, 2017 9:18 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

Continue Reading

ThursdayAug 24, 2017 3:19 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Licensed to Grow Cannabis by Feds in Canada

An early mover in the Canadian cannabis space Serving Canada’s most populous province New funding deal signed for $15 million at $2.25 per share As befits its status as a first mover in the Canadian cannabis space, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) is racing ahead with plans to supply the medical marijuana needs of Canada’s most populous province. Construction plans at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot phase 1 project have been expanded to 100,000 square feet. The company recently signed a…

Continue Reading

ThursdayAug 24, 2017 2:47 pm

Bollente Companies, Inc. (BOLC) Tankless Water Heaters Gain Ground in Robust Housing Construction Market

About 1,175,000 residential projects were completed in July, according to the U.S. Census Bureau Bollente’s trutankless water heaters are 99 percent efficient and provide hot water all the time The systems can run maintenance-free for 20 years or more, reducing demand on landfills The U.S. housing construction market remained robust in July 2017. A seasonal adjusted rate of 1,223,000 for building permits was reported for the month, and privately-owned housing starts were adjusted to 1,155,000. There were 1,175,000 housing completions for private residences, according to the United States Census Bureau (http://nnw.fm/vcw4L). Construction trends of energy efficient, water saving multi-family dwellings…

Continue Reading

ThursdayAug 24, 2017 11:59 am

SinglePoint (SING) Featured in Article Outlining Explosive Growth of Legal Cannabis Industry in North America

SinglePoint positioned for success in the cannabis market through its rapidly expanding portfolio of holdings positions Company reduces risk of changing state and federal laws by not touching the plant, but instead focusing on tools and services for the cannabis industry Proprietary bitcoin payment solution in development Specialized holding company SinglePoint, Inc. (OTC: SING) was featured prominently in a recent article (http://nnw.fm/gK79q) detailing the rapid growth in the North American legal marijuana market. The article explains how several companies, including SinglePoint, are taking advantage of this new market space. Experts are predicting a 25 percent compound annual growth rate for…

Continue Reading

ThursdayAug 24, 2017 11:06 am

AzurRx BioPharma, Inc. (NASDAQ: AZRX) Adds 6th Patient to MS1819 Phase II Clinical Trial

Early data from the first EPI patients enrolled in clinical studies utilizing AzurRx’s MS1819 therapy shows positive results Data indicates that MS1819, a recombinant lipase derived from the yeast Yarrowia Lipolytica, is showing a favorable safety profile and encouraging signs of efficacy and drug tolerance The study is being performed at four sites in Australia and New Zealand New York-based AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical company focused on the development of recombinant protein therapies for the treatment of gastrointestinal diseases and microbiome-related conditions. Patients with exocrine pancreatic insufficiency (EPI) related to chronic pancreatitis and cystic fibrosis are…

Continue Reading

ThursdayAug 24, 2017 9:00 am

Industry Movers Riding the Wave of Bitcoin’s Increasing Value

NetworkNewsWire Coverage: Bitcoin’s recent climb above the $4,500 mark is just one example of how its market capitalization continues to gain unprecedented reach. (http://nnw.fm/lGp8V) From cannabis to technology, bitcoin has impacted industries far and wide, but analysts believe that the cryptocurrency isn’t done climbing. A Goldman Sachs analyst recently predicted bitcoin could soon go for as high as $4,800. ChineseInvestors.com Inc. (CIIX) (CIIX Profile) is one business taking advantage of bitcoin’s success by setting up bitcoin payment acceptance through its wholly owned subsidiary, Chinesehempoil.com Inc. (http://nnw.fm/2ZjlL). SinglePoint, Inc. (SING) also continues to develop its bitcoin cannabis payment solutions, while technology…

Continue Reading

WednesdayAug 23, 2017 2:26 pm

AppSwarm, Inc. (SWRM) Rides Momentum to Drive Application Development Initiatives for 2017

The company reported revenues of $589,000 for 2016 Mergers and acquisitions have enabled AppSwarm to enter the e-commerce, health and education segments In-house software development has produced virtual reality products and expanded the app incubation/acceleration program AppSwarm (OTC: SWRM), a publicly traded technology development and incubation acceleration firm, has experienced a momentum in 2017 that has boosted its ability to acquire applications for any device type. Reaching out to young application developers and entrepreneurs has paid off. The royalty agreements, joint ventures, stock purchase agreements, partnerships, and purchases have expanded the company’s financial resources, while mergers and acquisitions have bolstered…

Continue Reading

WednesdayAug 23, 2017 1:30 pm

No Eclipse in Sight for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) as it Moves toward Clinical Trials

Proprietary biosynthesis process to produce cannabinoids Cannabinoid bioinformatics system that identifies optimal R&D pathways Lead candidate targeting billion dollar market Despite the awe-inspiring shadow cast by the moon on August 21, 2017, there’s no eclipse in sight for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). The Vancouver, Canada-based company continues its research and development (R&D) into the therapeutic benefits of cannabinoids, an activity that holds the promise of exceedingly rich reward. Peer valuations have skyrocketed, increasing the likelihood that unicorns may soon appear on the cannabis biotech landscape. With a triad of valuable core assets, it won’t be surprising if,…

Continue Reading

WednesdayAug 23, 2017 12:55 pm

Moxian, Inc. (NASDAQ: MOXC) Price Target of $5.25 Reaffirmed by Crystal Equity Research

Moxian praised for new joint venture strategy to help penetrate key markets in China Crystal Equity Research projects Moxian’s sales reaching $2.3 million in FY2018 Moxian adding three to its board of directors, including Liu Shu Juan, CEO of Shewn International Group, Inc. Moxian, Inc.’s (NASDAQ: MOXC) price target of $5.25 remains unchanged in the August 15, 2017, update report from Crystal Equity Research LLC (http://nnw.fm/gLF1A), which published its initial report on the company in January 2017. Crystal classified an investment in the company as a ‘speculative buy’ and made positive note of the firm’s joint venture with Shewn International…

Continue Reading

Contact us: 212.418.1217